other material
confidence high
sentiment positive
materiality 0.75
Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned
Revolution Medicines, Inc.
- 2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.
- 1L monotherapy (300 mg): ORR 47%, DCR 89% among 38 evaluable patients as of July 28, 2025 cutoff.
- 1L combo daraxonrasib 200 mg + gemcitabine/nab-paclitaxel: ORR 55%, DCR 90% in 31 evaluable patients.
- Grade ≥3 TRAEs: 34% monotherapy (2L), 35% (1L), 58% combo; most common rash, GI; 0% discontinuation in 2L.
- Company plans to initiate RASolute 303, a global Phase 3 trial in 1L PDAC comparing daraxonrasib ± GnP vs GnP.